(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 September 2025 (18.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/193930 A1

(51) International Patent Classification:
A61K 31/519 (2006.01) *A61K 47/68* (2017.01)
A61K 31/5365 (2006.01) *A61P 35/00* (2006.01)
A61K 39/395 (2006.01) *C07K 16/28* (2006.01)

(21) International Application Number:
PCT/US2025/019738

(22) International Filing Date:
13 March 2025 (13.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/565,372 14 March 2024 (14.03.2024) US
63/641,592 02 May 2024 (02.05.2024) US

(71) Applicant: **ZENO MANAGEMENT, INC.** [US/US]; 10275 Science Center Drive, Suite 200, San Diego, California 92121 (US).

(72) Inventors: **MA, Jianhui**; 10275 Science Center Drive, Suite 200, San Diego, California 92121 (US). **GUO, Xiao**; 10275 Science Center Drive, Suite 200, San Diego, California 92121 (US). **LEE, Catherine**; 10275 Science Center Drive, Suite 200, San Diego, California 92121 (US).

(74) Agent: **MILLER, Kimberly, J.**; KNOBBE, MARTENS, OLSON & BEAR, LLP , 2040 Main Street , 14th Floor, Irvine, California 92614 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: WEE1 INHIBITOR COMBINATION THERAPY




FIG. 2A

(57) Abstract: Disclosed herein is use of a combination of Compound (A), or a pharmaceutically acceptable salt thereof, and a maytansinoid, or an antibody-drug conjugate comprising a maytansinoid (including pharmaceutically acceptable salts) for treating a cancer.

[Continued on next page]

WO 2025/193930 A1

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*